— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing —

   — Ross Lobell named Vice President, Regulatory Affairs —

Norwood, MA, May 22, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today the appointment of Robert Discordia, Ph.D., as Vice President, Pharmaceutical Development & Manufacturing, and Ross Lobell as Vice President, Regulatory Affairs. Dr. Discordia will oversee all aspects of Corbus’ chemistry, manufacturing and controls (CMC) for lenabasum and future drug candidates. Mr. Lobell will lead Corbus’ Regulatory Affairs and Quality Assurance groups.

“We are delighted to welcome Robert and Ross to the Corbus team.  We look forward to their important contributions to steering lenabasum through its remaining clinical development, potential approval and commercialization,” stated Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Dr. Discordia brings to Corbus more than 25 years of biopharmaceutical industry experience in CMC development and business operations. Dr. Discordia joins Corbus from Bristol-Myers Squibb (NYSE: BMY), where he most recently served as Executive Director, Business Operations, Procurement for Global Product Development & Supply. While serving in that position, Dr. Discordia was responsible for managing the strategic business partnerships for the company’s small molecule development and commercial manufacturing. Prior to that, he served as Bristol-Myers Squibb’s Group Director & Head, External Partner Management, Pharmaceutical Development at Bristol-Myers Squibb. Most notably, he held leading roles in the CMC development and launch of multiple medicines, including TAXOL^®, BARACLUDE^® and ELIQUIS^®. Dr. Discordia received his Ph.D. in Organic Chemistry from Syracuse University and a Bachelor of Science in Chemistry from SUNY Cortland. He completed his postdoctoral training at The Research Institute of Scripps Clinic and the University of California, San Diego.

Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory strategies and operations. Prior to his appointment at Corbus, he held various leadership positions across several global pharmaceutical companies, including Schering-Plough, Pfizer, Amgen and MedImmune, a member of the AstraZeneca Group. Over the course of his career, Mr. Lobell led development, registration and post-registration activities for small-molecule and biologic medicines in multiple therapeutic areas, including oncology, rheumatology, respiratory, women’s health and cardiology/lipid metabolism. Additionally, Mr. Lobell oversaw the development, submission and review management process for New Drug Applications, Biologics License Applications, and supplemental efficacy applications to expand labeling. Mr. Lobell received his Bachelor of Science in Biology from Lebanon Valley College.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Source: Corbus Pharmaceuticals Holdings, Inc.

Investor Contacts:

Institutional Investor Inquiries
Ted Jenkins, Senior Director, Investor Relations and Communications
Corbus Pharmaceuticals, Inc.
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com

All Other Investor Inquiries
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (833) 475-8247
Email: crbp@jtcir.com

Media Contact
Eliza Schleifstein
Scient Public Relations
Phone: + 1 (917) 763-8106
Email: eliza@scientpr.com  

Released May 22, 2018